Collectively, these findings reveal preservation of the metabolic actions of two GLP-1 medicines, semaglutide and tirzepatide, yet inability to detect improvement in structural and functional parameters of neurodegeneration in two mouse models of Alzheimer's disease. The gene discussed is GLP1R; the disease is early-onset autosomal dominant Alzheimer disease.